Cyclic AMP (cAMP) is an important second messenger that regulates a wide range of physiological processes. In mammalian cutaneous melanocytes, cAMP-mediated signaling pathways activated by G-protein coupled receptors (GPCRs), like melanocortin 1 receptor (MC1R), play critical roles in melanocyte homeostasis including cell survival, proliferation and pigment synthesis. Impaired cAMP signaling is associated with increased risk of cutaneous melanoma. Whereas mutations in mitogen activated protein kinase (MAPK) pathway components are the most frequent oncogenic drivers of melanoma, the role of cAMP in melanoma is not well understood. Here, using the BRAF(V600E)/PTEN-null mouse model of melanoma, topical application of an adenylate cyclase agonist, forskolin (a cAMP inducer), accelerated melanoma tumor development in vivo and stimulated the proliferation of mouse and human primary melanoma cells, but not human metastatic melanoma cells in vitro. The differential response of primary and metastatic melanoma cells was also evident upon pharmacological inhibition of the cAMP effector protein kinase A (PKA). Pharmacological inhibition and small interfering RNA (siRNA)-mediated knockdown of other cAMP signaling pathway components showed that EPAC-RAP1 axis, an alternative cAMP signaling pathway, mediates the switch in response of primary and metastatic melanoma cells to cAMP. Evaluation of pERK levels revealed that this phenotypic switch was not correlated with changes in MAPK pathway activity. Although cAMP elevation did not alter the sensitivity of metastatic melanoma cells to BRAF(V600E) and MEK inhibitors, the EPAC-RAP1 axis appears to contribute to resistance to MAPK pathway inhibition. These data reveal a MAPK pathway-independent switch in response to cAMP signaling during melanoma progression.
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Introduction
Cyclic AMP (cAMP) signaling, triggered by the activation of stimulatory G protein-coupled receptors (GPCRs), regulates a wide range of physiological functions. In mammalian melanocytes, the cAMP signaling cascade is activated by the binding of α-melanocyte stimulating hormone to melanocortin 1 receptor (MC1R, a GPCR) leading to the expression of micropthalmia-associated transcription factor (MITF), the melanocyte master regulator (1) .
Human MC1R gene polymorphisms that result in cAMP signaling impairment are associated with a fair skin and red hair color phenotype and increased risk of melanoma (2) (3) (4) . The MC1R-cAMP pathway has been implicated in reduction of ultraviolet-induced oxidative stress via activation of p53, suggesting a possible role for cAMP signaling in preventing melanocyte transformation (5) .
Mutation of BRAF and NRAS, components of the mitogen activated protein kinase (MAPK)
pathway are oncogenic drivers in majority of cutaneous melanomas; mutations and amplification of MITF have also been reported (6, 7) . Causative genetic alterations in the components of the cAMP signaling pathway have not been reported in melanoma. However, during transformation of mouse melanocytes by NRAS(G12V), cAMP is reported to be downregulated by its degradation by phosphodiesterase 4, allowing reactivation of CRAF to overcome the negative regulation of MAPK pathway by phosphorylation of BRAF by ERK (8, 9) . It has also been reported that cAMP signaling, through protein kinase A (PKA) activity, inhibits cdc25B phosphatase and delays cell cycle progression in human melanoma cell lines (10) . cAMP signaling has also been implicated in acquired resistance to MAPK inhibition in BRAF(V600E) melanomas (11) , highlighting the need for a better understanding of crosstalk between cAMP signaling and MAPK signaling in melanoma. cAMP can signal via two alternative pathways-the PKA-CREB axis and the exchange protein directly activated by cAMP (EPAC)-RAP1 axis. EPAC, also known as cAMP-dependent RAPGEF, is a guanine nucleotide exchange factor (GEF) for the Ras-related protein 1 (RAP1), which activates RAP1 by GDP-GTP exchange. There are two EPAC isoforms-EPAC1 (RAPGEF3) and EPAC2 (RAPGEF4) (12, 13) . There is limited information on the role of EPAC-RAP1 signaling in melanoma, limited to its role in cell migration and tumor growth in mouse xenograft models (14) (15) (16) . Contradictory roles have been assigned to RAP1 in melanoma. For example, although higher activated RAP1 (GTP bound RAP1) levels are found in human metastatic melanoma cell lines and tissues compared to normal melanocytes (17) , RAP1 has been shown to impair vasculogenic mimicry, an indicator of melanoma aggressiveness (18). The role of EPAC-RAP1 signaling axis in mediating the effects of cAMP in melanocytes and melanoma is not completely understood.
In this study, we found that topical application of forskolin (FSK), an adenylate cyclase agonist that elevates cAMP, accelerated tumor development and promoted tumor growth in a genetic model of mouse melanoma. Elevation of cAMP also stimulated the growth of both mouse and human primary melanoma cells, but inhibited the growth and survival of human metastatic melanoma cells. Employing chemical and genetic modulation of the EPAC-RAP1 axis, an alternative cAMP signaling pathway, we show that inhibition of EPAC-RAP1 signaling decreased survival of human primary melanoma cells but increased proliferation and survival of metastatic melanoma cells. We propose that EPAC acts as a signaling switch in mediating the opposing roles cAMP plays during melanoma progression. 
Materials and Methods

Animals
Cell culture
Normal human melanocytes were obtained from human neonatal foreskin and cultured as described previously (20 (22) and colonies were counted.
Lentiviral shRNA
Cells were (in 60mm plates) transduced with CREB1 shRNA lentiviruses (CLONE ID TRCN0000011085 or TRCN0000007308) or scrambled shRNA (RHS6848) (Thermo Scientific).
After 48 hours of transduction, medium was replaced with selection medium (5µg/mL puromycin) and cells were maintained in puromycin medium.
RAP1-GTP pulldown assay
on of tissue extracts of representative tumors from 2-3 different mice showed no significant difference in pERK levels between tumors from control and FSK treated mice (Fig. S1B) .
Next, to test whether melanoma cells in these mouse tumors are intrinsically responsive to cAMP elevation or the tumor microenvironment is required for their response to cAMP, we established cell lines from tumors [as described in (21)] excised from a DMSO treated animal 8 weeks after 4-HT application. Western blot analysis of cell lysates for expression of melanocyte differentiation marker tyrosinase (Tyr), the presence of dark black pigment, and the decreased survival upon inhibition of BRAF(V600E) confirmed that these proliferating cells in the culture are from melanoma tumors ( Fig. S1C and S1D) . Treatment of these cells with FSK increased their proliferation (Fig. 1D ). Treatment with FSK had similar growth stimulatory effect on human cutaneous primary BRAF mutant melanoma cells (Fig. 1E) . These data suggest cAMP promotes melanoma development in vivo and enhances the growth of primary melanoma cells in vitro.
cAMP negatively regulates the growth, survival and migration of metastatic melanoma cells Next, we aimed to study the role of the endogenous cAMP signaling pathway on melanoma growth, survival, and migration. First, we quantified the activation status of the cAMP pathway in a series of exponentially growing human metastatic melanoma cell lines (passage ≤30) harboring either wild type BRAF and NRAS or mutant BRAF or mutant NRAS. The steady state
[cAMP] in these metastatic melanoma cell lines did not show correlation with the MAPK pathway mutation status (Fig. S2A) . The intracellular [cAMP] in melanoma cell lines pmol/mg-protein) was lower than [cAMP] in normal human melanocytes (NHM) cultured in a cAMP inducing medium (51.28 pmol/mg-protein) (Fig. S2A) . Activity of CREB, as measured by its phosphorylation and by CRE-luciferase reporter activity, did not correlate with the intracellular [cAMP] suggesting a dysregulation of the cAMP-CREB signaling axis in melanoma cells ( Fig. S2B and Fig. S2C ). Neither constitutive levels of pCREB nor its transcriptional activity correlated with MAPK activity levels as measured by pERK. Taken together, these results show a dysregulation of cAMP signaling in melanoma independent to MAPK pathway mutation status (Fig. S2D) .
To confirm that treatment with FSK increases [cAMP], we measured the intracellular [cAMP] in both NHM and melanoma cells (Fig. 3SA-B) . FSK treatment increased [cAMP] in melanoma cells to a concentration comparable to or higher than in NHM (for example, up to ≥40 pmol/mg protein in MRA5 cells and MRA-6 and >100 pmol/mg protein in MRA9, respectively) ( Fig. S2A and Fig. S3B ). Elevation of [cAMP] decreased the survival and the proliferation of MRA-6 and MRA-4 cells but had no effect on MRA-5 cells ( Fig. 2A and S2C) . However, sustained activation of ACs decreased the clonogenicity of all melanoma cell lines including MRA-5 ( (Fig. S4A) . Accordingly, the effects of AZD6244 and PLX4032 on the survival of these melanoma cells correlated with a decrease in pERK (Fig. 2B -Left   panel) . Elevation of [cAMP] in these metastatic melanoma cell lines by FSK also decreased pERK levels (Fig. 2B -Right panel) , suggesting that the inhibitory effects of elevated [cAMP] on metastatic melanoma cell survival and growth might be due to downregulation of MAPK signaling.
cAMP signaling has been implicated in mechanisms of acquired resistance of melanoma to MAPK pathway inhibition (11, 23) . Therefore, we asked whether treatment with FSK increases the sensitivity of melanoma cells to MAPK pathway inhibition. Elevation of [cAMP] did not significantly change the sensitivity of melanoma cells to the BRAF(V600E) inhibitor PLX4032 or MEK inhibitor AZD6244 (Fig. 2C and Fig. S4B ), although cAMP elevation appeared to sensitize the cells to lower concentrations of the BRAF(V600E) inhibitor PLX4032 (Fig. 2C) .
Moreover, cAMP elevation did not sensitize the intrinsically resistant MRA-5 cell line to killing by MAPK pathway inhibition (Fig. 2C) . Thus, although elevation of [cAMP] decreased MAPK activity, treatment with FSK did not have marked effect on inhibition of survival by MAPK pathway inhibitors.
To understand if cells that acquire resistance to MAPK pathway inhibition also acquire resistance to growth inhibition by elevated [cAMP], we generated MRA-6 cell lines (MRA-6BR and MRA-6MR) resistant to PLX4032 and AZD6244, respectively. (Fig. S4C -top panel) .
Western blot analysis showed that while MEK inhibitor-resistant MRA-6MR cells had higher pERK levels, BRAF(V600E) resistant MRA-6BR cells had lower pERK levels compared to their parental cells, showing that the survival of these resistant melanoma cell lines in response to MAPK inhibition is not related to pERK levels ( Fig. S4C -bottom panel) . Interestingly, these 
MAPK pathway inhibition resistant cell lines remained sensitive to cAMP elevation (Fig. S4D) , although cAMP elevation did not alter the response of the resistant cell lines to PLX4032 or AZD6244 inhibitors (Fig. 2D and Fig. S4E ). These data further support the conclusion that the inhibitory effect of elevated [cAMP] on growth and survival of metastatic melanoma cells is independent of MAPK activity. Considering the reported roles of AKT/mTOR signaling in human melanoma (19) we investigated the effects of cAMP modulation on this signaling pathway. In FSK treated cells, we did not observe consistent change in the activation of AKT (Ser473 and Thr308 phosphorylation) or mTOR (Ser2448 and Ser2481 phosphorylation) in neither primary (Fig. S5A) nor metastatic (Fig. S5B ) melanoma cell lines.
Differential roles of the cAMP signaling mediator Protein Kinase A (PKA) in primary and metastatic melanoma cells
Cellular responses to cAMP signaling are mainly mediated through activation of PKA, which subsequently phosphorylates CREB at Ser133. Interestingly, pharmacological inhibition of PKA with 5µM H89 decreased the proliferation of primary melanoma but not metastatic melanoma cells (Fig. 3A) . At this concentration, H89 decreased the Ser133 phosphorylation of CREB in both primary and metastatic melanoma cells (Fig. 3B-C) . This data suggest that the PKAdependent activation of CREB does not contribute to the proliferation of metastatic melanoma cells. Although treatment with the PKA inhibitor resulted in an increase in pERK levels (Fig.   3B ), this upregulation of ERK phosphorylation was not associated with enhanced growth of these primary melanoma cells (Fig. 3A) . Conversely, in metastatic melanoma cells, inhibition of PKA resulted in reduced pERK, but this reduction in pERK was not associated with decreased cell survival (Fig. 3A) . Next, we asked whether the decrease in ERK phosphorylation observed (Fig. S6A) . These data show that the effects of cAMP on survival of metastatic melanoma cells are not dependent on PKA activity or pERK levels.
To test the role of CREB in mediating cAMP signaling in melanoma cells, we employed lentiviral shRNA to knockdown CREB. Stable cell lines with CREB1 knockdown (CREB-KD) showed decreased pCREB levels (Fig. 4A) . Interestingly, CREB KD cells showed higher pERK (Fig. 4A) , but this upregulation of ERK activation in CREB-KD cells was accompanied by inhibition of growth and clonogenecity ( Fig. 4B and Fig. S7) . Moreover, elevation of [cAMP] by FSK further decreased the clonogenecity of CREB-KD cells (Fig. 4B and Fig. S7B metastatic melanoma than in primary melanoma cells (Fig. S8A) . Similarly, western blot analysis showed that RAP1A/B is upregulated in primary and metastatic melanoma cells compared to melanocytes (Fig. S8B) .
We used pharmacological inhibition of EPAC with ESI-09 [a propionitrile compound that targets the cAMP-binding domain (24, 25) ] to investigate the role of EPAC-RAP1 signaling in melanoma cell survival and growth. The effect of EPAC inhibition on activation of RAP1 (GTPbound RAP1) was assessed by pulldown assay using GST-RalGDS-RBD fusion protein followed by western blot analysis (Fig. 5A) . Treatment of primary melanoma cells with the EPAC inhibitor ESI-09 decreased their growth (Fig. 5B -top panel) , whereas a similar treatment with the EPAC inhibitor stimulated the growth of metastatic melanoma cells (Fig. 5B -bottom   panel) . Next, we employed EPAC1/2 siRNA to confirm the effects of chemical inhibition of EPAC on the survival of human melanoma cells (Fig. S8C) . Knockdown of EPAC1/2 did not affect the survival of primary melanoma cells (Fig. S8D) but increased the proliferation in the majority of metastatic melanoma cell lines (Fig. S8E) . The difference between chemical and genetic inhibition of EPAC in primary melanoma cells might be due a higher efficacy of ESI-09 in inhibiting EPAC activity. Nonetheless, these data confirm the differential response of primary and metastatic melanoma to EPAC signaling. Furthermore, treatment with higher concentrations of EPAC1/2 inhibitor ESI-09 promoted the survival of metastatic melanoma cell lines with no evidence of cytotoxicity (Fig. S9A) . EPAC inhibition also decreased the sensitivity of metastatic melanoma cells to the BRAF(V600E) inhibitor PLX4032 and the MEK inhibitor AZD6244 (Fig. 5C and Fig. S9B) , suggesting a role for EPAC in resistance to MAPK pathway inhibition. However, this response could also be explained by the increased proliferation in the presence of EPAC inhibitor rather than a direct effect on their sensitivity to MAPK inhibition. Western blot analysis showed that EPAC inhibition paradoxically increased phosphorylation of ERK, suggesting a MAPK-independent mechanism of action of the alternative cAMP signal mediator, EPAC (Fig. 5D) . Although some effects of EPAC inhibition on the sensitivity of melanoma cells to BRAF inhibitor could be due to increased proliferation, contribution of increased MAPK activity in decreasing the sensitivity of these BRAF(V600E) melanoma cells to MAPK pathway inhibitors cannot be ruled out.
Next, considering the critical role of MITF in melanocytes and melanoma, we investigated the effects of EPAC inhibition on MITF and its target genes tyrosinase (TYR) and TRP1 in primary and metastatic melanoma cell lines (Fig. S10A-B) . Western blot analysis showed that, although there is a decrease in TYR protein in one primary melanoma cell (WM1862), the low MITF cell line WM1552C does not express TYR but its survival is decreased upon EPAC inhibition similar to WM1862 (Fig. S10A and Fig. 5B) . Moreover, metastatic melanoma cell lines did not show any significant change in MITF or TYR expression (Fig. S10B) . Taken together, these data show that treatment with the EPAC inhibitor did not cause marked change in MITF levels, although expression of TYR and TRP1 was not always correlated with MITF expression.
To confirm the role of RAP1 in mediating the effects of EPAC, we performed RAP1 knockdown using siRNA targeting either total RAP1 (both RAP1A and RAP1B) or RAP1A and RAP1B alone (Fig. 6A-B) . RAP1A/B knockdown resulted in decreased survival of primary melanoma cells (Fig. 6C) . In contrast, RAP1A/B knockdown increased proliferation of metastatic melanoma cells (Fig. 6D) . Similarly, transduction of cells with adenovirus expressing the constitutively active RAP1B (G12V)-GFP/FLAG protein (Fig. S11A-B) increased the proliferation of primary melanoma cells (Fig. S11C) but decreased the survival of metastatic melanoma cells (Fig. S11D) . Again, the effects of RAP1 inhibition on survival and proliferation of primary and metastatic melanoma cells did not correlate with pERK levels (Fig. 6A-B) . These data show a role for RAP1 in melanoma cell survival and proliferation, where it acts as a switch in mediating the response of primary and metastatic melanoma cells to cAMP in a MAPKpathway independent manner. Taken together, these data suggest that cAMP plays opposing roles during melanoma progression (Fig. 6E) , switching from a pro-survival role in primary melanoma to antiproliferative role in metastatic melanoma, and that this switch in response to cAMP is mediated by the EPAC-RAP1 axis. 
Discussion
In this study, we show that cAMP signaling plays opposing roles in primary and metastatic melanoma cells and this switch in the role of cAMP signaling is mediated by EPAC-RAP1 axis.
Although the role of cAMP signaling in melanocyte transformation has been studied in vitro, its role in melanoma tumor development in vivo is not well understood. For example, elevation of cAMP signaling in mouse melanocytes in vitro by treatment with FSK was shown to block their transformation by NRAS(G12V) (8, 9) . Activation of MC1R and the cAMP/PKA pathway has been linked to attenuation of oxidative stress (through activation of p53) in human melanocytes in culture, suggesting a negative role for cAMP in melanocyte transformation (5) . Our data using the Braf CA /Pten -/-mouse melanoma model, however, show that activation of cAMP signaling accelerates melanoma tumor development in vivo.
In melanocytes, melanin synthesis is stimulated by cAMP elevation (26) (27) (28) (29) . Melanin derivatives can induce DNA damage (30) and pheomelanin production was shown to be sufficient to induce melanoma in Braf CA/CA mice with Mc1r-null allele (29) . Despite the differences observed in the latency and tumor growth between FSK and DMSO treated mice with wild type Mc1r, there was no difference in the tumor melanin content.
Melanoma tumor cells in this mouse model are dependent on the MAPK pathway for their survival as shown by their sensitivity to MAPK inhibitors both in vivo (19, 31) and in vitro [(19,31) and Fig S2A] . However, MAPK activation, as measured by pERK levels, has been reported to be a poor indicator of mutation status of BRAF or NRAS oncogenes or the antiproliferative effects of MEK inhibitor on human melanoma cells (32, 33) . Consistent with this notion, we found that tumors from FSK treated mice, although containing a larger population of proliferative cells (as seen by the intense Ki67 immunostaining) as compared to controls, did not 
show correlations of increased growth with pERK levels, suggesting a MAPK pathwayindependent mechanism for the effects of elevated cAMP in melanoma tumor growth. Figure 5A and 5B were performed simultaneously using same lysates from same experiment; therefore, same β-Tubulin is used. 
Melanoma cells derived from
